MDXH
MDxHealth SA
NASDAQ · Healthcare · Medical - Diagnostics & Research · BE
$0.18
−5.63%Price chart
Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29
Key dataOct 29, 2026
Open$0.19
From 52W high−96.32%
Volume421301.00
Market cap$17.29M
P/E (TTM)—
P/S (TTM)0.2x
Div yield—
Key dataOct 29, 2026
Open
$0.19
From 52W high
−96.32%
Volume
421301.00
Market cap
$17.29M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−13.4x
P/E (TTM)
—
RSI (14)
23.4
MomentumView details →
1D Return
−5.63%
YTD Return
−95.07%
SummaryUpdated Jun 1, 2026
MDxHealth SA (NASDAQ:MDXH) is a Belgian-based commercial-stage precision diagnostics company that specializes in urologic testing solutions. Founded in 2003 and originally known as OncoMethylome Sciences SA, the company changed its name to MDxHealth SA in 2010 and went public on NASDAQ in November 2021. Headquartered in Herstal, Belgium, MDxHealth has established itself as a focused player in the prostate cancer diagnostics market, offering a comprehensive menu of genomic and epigenetic tests that help physicians make more informed decisions about patient care while reducing the need for invasive procedures.
Similar companies
Latest newsMore news →
MDxHealth SA announced that it will release its financial results for the third quarter ended September 30, 2026, after market close on November 12, 2026, and host a conference call and webcast that day.13h agoMdxhealth reported second quarter 2026 financial results with revenue growth of 16% to $27.2 million.78d ago